-transparent.png){kind=logo}
We have determined metabolic parameters for androstenedione (A) in chronically catheterized late gestation (day 130) sheep fetuses. The MCR (MCRA) was 3210 +/- 229 (SEM, n = 12) ml/min, the fetal arterial whole blood concentration of A [A] was 65 +/- 5 pg/ml, and the blood production rate (PRA) was 204 +/- 20 ng/min. Pulsatile administration of ACTH in amounts that raised fetal arterial plasma cortisol concentrations by 5- to 7-fold increased [A] to 154 +/- 20 pg/ml and PRA to 471 +/- 31 ng/min with no change in MCRA. In the presence of metopirone to block fetal adrenal cortisol output, ACTH treatment still provoked elevations in [A] (to 198 +/- 23 pg/ml) and PRA (539 +/- 158 ng/min), without altering MCRA. The major radiolabeled product in blood of infused [3H]A was [3H]testosterone; smaller amounts of phenolic steroids were formed. Extensive metabolism of [3H]A occurred in whole blood in vitro. The major product was [3H]testosterone; the 17-oxidoreductase activity was associated with the red blood cells. Umbilical vein [A] was greater than umbilical artery [A]; ACTH treatment increased [A] in both vessels. Concomitant metopirone abolished the arteriovenous difference by eliminating the ACTH-induced increase in venous [A], although arterial [A] rose significantly. The venous [A] and the arteriovenous gradient were restored with exogenous glucocorticoid treatment to the fetus. Collagenase-dispersed fetal adrenal cells secreted A. Adrenal cells from fetuses pretreated with ACTH in vivo had higher basal and ACTH-induced output of A in vitro than cells from fetuses pretreated with saline in vivo. We conclude that the MCRA in fetal sheep is extremely high, in part due to conversion of A to testosterone in fetal blood. The elevated PRA after ACTH plus metopirone and the lack of an umbilical arteriovenous gradient of [A] in this, but not other groups of fetuses, suggests a source of A production independent of the cortisol-induced changes in the placenta. Direct evidence is provided for fetal adrenal secretion of A which is enhanced by ACTH pretreatment of the fetus in vivo and for the utilization of circulating A in the fetus as a precursor for estrogen in both fetal and maternal compartments.
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
July 1994,
The American journal of physiology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
December 1983,
Journal of developmental physiology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
May 1998,
The Journal of physiology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
January 1995,
The Journal of physiology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
March 1981,
Endocrinology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
November 2012,
The Journal of physiology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
June 2001,
The Journal of physiology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
March 1993,
Neuroendocrinology,
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
June 1975,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
B F Mitchell, and
S J Lye, and
L Lukash, and
J R Challis
November 2000,
Endocrinology,
